pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Drugs
by stage
  • Marketed
  • Phase 3
  • Phase 2
  • Phase 1
  • Preclinical
browse
  • Most catalysts
  • Recently active
  • All drugs →
  • Companies
  • Patent cliff
Calendar
what
  • Trial readouts
  • PDUFA dates
  • Approvals
  • Earnings
when
  • Upcoming
  • Month grid
  • Recently passed
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
  • Drugs
  • Calendar
  • Companies
Hubs
  • Topics
  • Patent cliff
  • Publications
  • Readouts
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
  1. pharmadog
  2. ›drugs
  3. ›Hemophilia A
drug
save

Hemophilia A

Preclinicalupdated 6mo ago
by Sernova Biotherapeutics Inc
Preclinical
community read0 votes

🐶 often sniffed alongside

top 7
  • tagHemophilia5 co-mentions · 3 sources
  • companyAltasciences Co Inc1 co-mentions · 1 sources
  • drugefanesoctocog alfa1 co-mentions · 1 sources
  • tagCRO/CDMO1 co-mentions · 1 sources
  • drugicosapent ethyl1 co-mentions · 1 sources
  • drugNN-74421 co-mentions · 1 sources
  • companyPSI CRO AG1 co-mentions · 1 sources

all catalysts(0)

nothing on the calendar yet

News(10)

  • Novo’s CEO still looking for deals to ‘close some of the gaps,’ as misfires hit profits
    Novo’s CEO has told Fierce that the company remains on the hunt for deals that “close some of the gaps” in its pipeline, as the Big Pharma reports billions of dollars in impairment charges from a s…
    fiercebiotech · 13d ago
  • Sanofi targets late-phase and commercial M&A to offset looming Dupixent decline
    Focused on ensuring growth beyond Dupixent, Sanofi wants to acquire derisked assets that may benefit from the French pharma’s commercial capabilities, executives said on Friday as they reported thi…
    biospace · 17d ago
  • Roche’s pipeline trim claims Poseida’s off-the-shelf CAR T asset
    Aside from RG6540, Roche also discontinued a host of other early-stage assets, including an antisense oligonucleotide for Alzheimer’s disease and a small-molecule candidate for geographic atrophy.
    biospace · 25d ago
  • FDA extends review of Novo’s hemophilia A drug, citing manufacturing issues
    Despite the regulatory delay, Novo is still expecting a 2027 launch for its hemophilia A drug denecimig.
    biospace · 1mo ago
  • FDA delays Novo’s hemophilia A drug review over factory issues
    US regulators have extended their review of Novo's hemophilia A injection denecimig because of issues at an unnamed manufacturing facility. The FDA attributed the delay to “ongoing facility remedia…
    endpoints · 1mo ago
  • STAT+: Pharmalittle: We’re reading about a Vaxcyte pneumococcal shot, increasing pharma M&A, and more
    Vaxcyte said its pneumococcal vaccine hit the primary endpoints in a Phase 3 clinical trial, setting up a competition with Pfizer and Merck
    stat · 1mo ago
  • CHMP backs Novo’s hemophilia A drug and seven other medicines
    Novo won regulatory backing for its hemophilia A preventive drug from the European Medicines Agency's human medicines committee, which also recommended approving seven other new drugs and 11 label…
    endpoints · 1mo ago
  • Roche, Dualitas team up to find bispecific drugs for immune diseases
    Through a research deal worth up to $1 billion, Dualitas will sift through more than 300,000 possible bispecific combinations in the hopes of unearthing new and differentiating treatments.
    biopharma_dive · 2mo ago
  • Roche signs $1B deal with Dualitas to pair up on big bispecific screening drive
    Roche is paying Dualitas Therapeutics $36.5 million upfront to screen over 300,000 novel bispecific combinations in search of new treatments for immunology and inflammation diseases.
    fiercebiotech · 2mo ago
  • Oz says ‘AI-based avatars’ can help rural communities. Some leaders disagree
    Feds invest in AI for heart failure, vaccines and this year's midterms, and more health news from Morning Rounds
    stat · 2mo ago
view all news mentions →
indication
Hemophilia A (Factor VIII Deficiency)
phase
preclinical
Data sources
ClinicalTrials.gov
last refreshed 4h ago
Found something off?
🐶 something off?

Report a data issue

Tell Bork what looks wrong — wrong sponsor, stale phase, mislinked ticker, anything. We’ll triage and fix.

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?